Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Related MRK
Markets Marginally Lower Ahead Of Earnings Season
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline
Stocks Poised to Slip from Record Highs (Fox Business)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Posted-In: News Upgrades Price Target Markets Analyst Ratings

 

Most Popular

Related Articles (MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free